참고문헌
- Park B, Choi KS, Lee YY, Jun JK, Seo HG. Cancer screening status in Korea, 2011: results from the Korean National Cancer Screening Survey. Asian Pac J Cancer Prev 2012;13(4):1187-91. https://doi.org/10.7314/APJCP.2012.13.4.1187
- Kang SH. Survival from the First Recurrence and the Prognostic Factors of Patients with Recurrent Breast Cancer. Ann Surg Treat Res 2007;73(3):210-5.
- Yoon HS. Survival Analysis and Its Prognostic Factors after Distant Relapse in Breast Cancer Patients Purpose: Little attention has been paid to. Ann Surg Treat Res 2003;64(2):101-8.
- Park JG, Bang YJ, Ha SW. Oncology. Seoul: Ichokak; 2012, p. 596.
- Woo HD, Kim HS, Lee JH, Kim HM, Han SW, Kim SY, et al. Toxicity and Tolerability Study of Adjuvant TAC Regimen Chemotherapy in Korean Patients with Breast Cancer. J Breast Cancer 2011;14(S):S44-9. https://doi.org/10.4048/jbc.2011.14.S.S44
- Seo JY, Yi M. Distress and Quality of Life in Cancer Patients Receiving Chemotherapy. Asian Oncol Nurs 2015;15(1):18-27. https://doi.org/10.5388/aon.2015.15.1.18
- Lee NH, Lee KW, Yoo HS, Lee JS. A Preliminary Study for Development of Clinical Practice Guidelines of Korean Medicine in Breast Cancer. J Korean Obstet Gynecol 2016;29(2):47-65. https://doi.org/10.15204/JKOBGY.2016.29.2.047
- Kim JH, Bae KR, Park SJ, Cho CK, Yoo HS. A Case of Patient with Recurring Non-Small Cell Lung Carcinoma Treated with Samchilchoongcho-Jung in Conjunction with Afatinib. J Int Korean Med 2017;38(1):72-80.
- Li X, Yang G, Li X, Zhang Y, Yang J, Chang J, et al. Traditional Chinese medicine in cancer care: a review of controlled clinical studies published in chinese. PLoS One 2013;8(4):e60338. https://doi.org/10.1371/journal.pone.0060338
- Greenlee H, Balneaves LG, Carlson LE, Cohen M, Deng G, Hershman D. Clinical practice guidelines on the use of integrative therapies as supportive care in patients treated for breast cancer. J Natl Cancer Inst Monogr 2014;2014(50):346-58. https://doi.org/10.1093/jncimonographs/lgu041
- Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R. New response evaluation criteria in solid tumours: Revised RECIST guideline(version 1.1). Eur J Cancer 2009;45(2): 228-47. https://doi.org/10.1016/j.ejca.2008.10.026
- National Cancer Institute. Common Terminology Criteria for Adverse Events(CTCAE) v.4.0, 2010. Available at http://evs.nci.nih.gov/ftp1/CTCAE/About.html)
- Cho DI, Kim HS. The literature review for prescription of static blood. Daejeon University Korean Medicine Research Institute 1997;5(2) :265-79.
- Park JA, Choi SH, Ahn GS, Moon DJ. A Study on the Effect of Samchilgeun(San qi gen) on Thrombosis and elevated Blood Viscosity. JPPKM 1992;7(1):15-26.
- Wang W, Zhang X, Qin JJ, Voruganti S, Nag SA, Wang MH, et al. Natural product ginsenoside 25-OCH3-PPD inhibits breast cancer growth and metastasis through down-regulating MDM2. PLoS One 2012;7(7):e41586. https://doi.org/10.1371/journal.pone.0041586
- Wang P, Cui J, Du X, Yang Q, Jia C, Xiong M, Yu, et al. Panax notoginseng saponins (PNS) inhibits breast cancer metastasis. J Ethnopharmacol 2014;154(3):663-71. https://doi.org/10.1016/j.jep.2014.04.037
- Bernard MM, McConnery JR, Hoskin DW. [10]-Gingerol, a major phenolic constituent of ginger root, induces cell cycle arrest and apoptosis in triple-negative breast cancer cells. Exp Mol Pathol 2017;102(2):370-6. https://doi.org/10.1016/j.yexmp.2017.03.006
- Jiang K, Lu Q, Li Q, Ji Y, Chen W, Xue X. Astragaloside IV inhibits breast cancer cell invasion by suppressing Vav3 mediated Rac1/MAPK signaling. Int Immunopharmacol 2017;42:195-202. https://doi.org/10.1016/j.intimp.2016.10.001
- Bang SH, Kwon KR, Yoo HS. Two cases of Non-Small Lung Cancer Treated with Intravenous Cultivated Wild ginseng Pharmacopuncture. Journal of Phramacopuncture 2008;11(2):13-9.
- Jia WW, Bu X, Philips D, Yan H, Liu G, Chen X, et al. Rh2, a compound extracted from ginseng, hypersensitizes multidrug-resistant tumor cells to chemotherapy. Can J Physiol Pharmacol 2004;82(7):431-7. https://doi.org/10.1139/y04-049
- Blum JL. The role of capecitabine, an oral, enzymatically activated fluoropyrimidine, in the treatment of metastatic breast cancer. Oncologist 2001;6(1):56-64. https://doi.org/10.1634/theoncologist.6-1-56
- Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999; 17(2):485-93. https://doi.org/10.1200/JCO.1999.17.2.485
- Han SA, Jang BH, Hwang DS, Suh HS. Experiences of Treatment-Related Side Effects and Supportive Care with Korean Medicine in Women with Breast Cancer - A Focus Group Study. J Korean Obstet Gynecol 2017;30(1): 85-94. https://doi.org/10.15204/jkobgy.2017.30.1.085
피인용 문헌
- 악성 난소 생식세포 종양 환자의 항암 치료 후 발생한 부작용 증상에 대한 한방치료 증례 보고 1례 vol.32, pp.4, 2018, https://doi.org/10.15204/jkobgy.2019.32.4.144
- 유방암 환자의 항암화학요법 후 한방병원 입원치료에 대한 일개 한방병원 환자 특성 및 치료 고찰 vol.33, pp.2, 2018, https://doi.org/10.15204/jkobgy.2020.33.2.077